Biogen inks Alkermes deal to defend multiple sclerosis turf

biogen
Alkermes is set to receive the first $50 million of the up to $200 million in milestones tied to the deal before the end of 2017.

Biogen has struck a deal to protect its blockbuster multiple sclerosis franchise Tecfidera from the threat of Alkermes’ ALKS 8700. The deal gives Biogen the exclusive worldwide rights to a candidate designed to match the efficacy and better the safety of a cornerstone of its commercial operation.

Cambridge, Massachusetts-based Biogen is paying Alkermes $28 million upfront to cover half of what its new partner has spent on developing the drug this year. Alkermes is also set to receive the first $50 million of the up to $200 million in milestones tied to the deal before the end of 2017. And it will free itself of the cost of developing ALKS 8700 in January, when Biogen will take full responsibility for funding its progress. 

Alkermes will retain responsibility for interactions with the FDA through to the approval of the drug. If all goes according to plan, Alkermes will pocket mid-teen royalties on worldwide sales of ALKS 8700.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

As the relatively modest dollar figures attached to the deal suggest, there is some doubt about how big a piece of the multiple sclerosis market ALKS 8700 can seize. ALKS 8700 is an oral prodrug of monomethyl fumarate. That allows the asset to follow the FDA’s 505(b)(2) regulatory pathway referencing Tecfidera, the scientific name of which is dimethyl fumarate.

RELATED: Alkermes takes its Tecfidera beater into clinical trials for MS

Alkermes came up with the formulation in a bid to offer multiple sclerosis patients the efficacy and convenience of Biogen’s oral Tecfidera without the gastrointestinal side effects. The biotech suggested late last month it may be on track to deliver such a drug when it posted data linking ALKS 8700 to a 3.7% adverse event-related dropout rate in a 570-patient study. 

The study is one of two phase 3 trials being run by Alkermes. The other study, which got underway this year, is comparing the gastrointestinal tolerability of ALKS 8700 and Tecfidera in 420 patients with relapsing remitting multiple sclerosis. 

Data from that trial will dictate how big of a threat ALKS 8700 poses to Tecfidera. Biogen will sleep easier in the run-up to the readout knowing it has already mitigated the risk.

Suggested Articles

LivaNova plans to restructure its heart valve operations, and will drop its investigational Caisson transcatheter mitral valve replacement altogether.

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million.